AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Amneal Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $1.81B | $1.75B | $1.75B | $1.75B | $1.71B | $1.71B | $1.69B | – | – | – | – | – | 58.1% | +5.6% |
| AvKARE | $732.28M | $738.33M | $744.73M | $704.37M | $665.33M | $672.70M | $662.95M | $642.02M | $614.42M | $572.36M | $531.75M | $490.33M | 23.5% | +10.1% |
| Specialty | – | – | – | – | – | – | – | – | – | – | – | $388.53M | – | – |
| Affordable Medicines | – | – | – | – | – | – | – | $1.61B | $1.57B | $1.52B | $1.47B | $1.51B | – | – |
| Specialty | – | – | $528.51M | $482.42M | $472.81M | $448.81M | $445.75M | $429.39M | $411.06M | $404.01M | $390.46M | $388.53M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $411.65M | $390.95M | $380.80M | $390.70M | $393.37M | $392.30M | $270.10M | – | – | – | – | – | +4.6% |
| AvKARE | $84.29M | $93.10M | $83.62M | $65.54M | $51.63M | $44.46M | $42.90M | $44.56M | $43.32M | $39.36M | $31.51M | $23.63M | +63.3% |
| Specialty | – | – | – | – | – | – | – | – | – | – | – | $87.38M | – |
| Affordable Medicines | – | – | – | – | – | – | – | $225.16M | $224.30M | $209.53M | $276.17M | $282.19M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Amneal Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.